Replies to post #43 on Vascular Biogenics Ltd (VBLT)

[Mjmillions]

One major risk is if VBL cannot begin Phase III on VB-111. They have abandoned one drug in Phase II already because it was no longer worth pursuing. That was VB-201.

But with the recent success of VB-111, it seems they'll move forward with their plan to begin Phase III mid-2015.